Central European Journal of Medicine

, Volume 9, Issue 2, pp 285–291 | Cite as

Differences on the prevalence of cervical HPV between Lithuania and Belarus

  • Zivile Gudleviciene
  • Daiva Kanopiene
  • Janina Didziapetriene
  • Raisa Smolyakova
  • Ekaterina Gutkovskaya
  • Alexander Zhukovec
  • Galina Kostevich
Case Report


In some countries the cervical cancer incidence and mortality rates are much higher compared to the European average. The differences of HPV and its type prevalence between countries and regions influence cervical cancer incidence and mortality. Regarding the differences in cervical cancer incidence and mortality in Lithuania and Belarus, the aim of this study was to describe HPV infection level and HPVs type distribution among two study groups of patients with moderate or severe cervical intraepithelial neoplasia (CIN2-3) and cervical cancer. Our data shows that 74.2% [95% CI: 63.64÷84.76] of Lithuanian patients with cervical cancer and 85.6% [95% CI: 85.53÷92.85] of the study group with CIN2-3 were HPV positive, while in the study groups of Belarusian patients HPV infection was detected in 92.6% [95% CI, 74.25÷98.71] and 65.4% [95% CI, 44.36÷82.06] cases respectively. HPV 16 was the most prevalent type in Lithuanian as well as in Belarusian patients of the study groups. HPV 18 in Lithuanian patients of the study group with cervical cancer was identified in 10.2% [95% CI: 1.73÷18.67] and in the study group with CIN2-3 — in 2.6% [95% CI: 0.95÷6.15] of cases. HPV 18 was not detected in Belarusian patients of both groups.


HPV infection Cervical intraepithelial neoplasia Cervical cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010. Available from:, accessed on day/month/yearGoogle Scholar
  2. [2]
    Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Nati Cancer Inst. 2006;98(5):303–315CrossRefGoogle Scholar
  3. [3]
    Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55(4):244–265PubMedCrossRefGoogle Scholar
  4. [4]
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527PubMedCrossRefGoogle Scholar
  5. [5]
    Munoz N, Castellsague X, de Gonzalez AB, Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(Suppl 3):1–10CrossRefGoogle Scholar
  6. [6]
    Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 2007;107:S2–S5PubMedCrossRefGoogle Scholar
  7. [7]
    Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010;117(2):S5–S10PubMedCrossRefGoogle Scholar
  8. [8]
    Anttila A, Ronco G: Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009;45(15):2685–2708PubMedCrossRefGoogle Scholar
  9. [9]
    Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L: European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition-Summary Document. Ann Oncol 2010;21(3):448–458PubMedCrossRefGoogle Scholar
  10. [10]
    WHO/Europe, European HFA Database, January 2012Google Scholar
  11. [11]
    Popendikyte V, Gulbinovic I, Paulauskiene V, Paulauskas D. High risk human papilloma virus detection and genotyping by multiplex PCR. Lietuvos akuserija ir ginekologija (Lithuanian Obstetrics and Gynecology) 2000;11:348–352Google Scholar
  12. [12]
    Cancer in Lithuania 2009. Institute of Oncology, Vilnius University. Cancer registry data, 2011 (available in Scholar
  13. [13]
    Gudlevicienė Z, Didziapetriene J, Ramael M, Uleckiene S, Valuckas KP: Human papillomavirus and p53 polymorphism in Lithuanian cervical cancer patients. Gynecol Oncol 2006;102(3):530–533PubMedCrossRefGoogle Scholar
  14. [14]
    Gudlevicienė Z, Didziapetriene J, Suziedelis K, Lapkauskaite L. Investigation of human papillomavisur its types and variants. Medicina (Lithuania) 2005;41(11):910–915Google Scholar
  15. [15]
    Istomin YP, Lapzevich TP, Chalau VN, Shliakhtsin SV, Trukhachova TV. Photodynamic therapy of cervical intraepithelial neoplasia grades II and III with Photolon. Photodiagnosis Photodyn Ther 2010;7(3):144–151PubMedCrossRefGoogle Scholar
  16. [16]
    Kulmala SM, Shabalova IP, Petrovitchev N, Syrjänen KJ, Gyllensten UB, Syrjänen SM; NIS Study Group. Prevalence of the most common high-risk HPV genotypes among women in three new independent states of the former Soviet Union. J Med Virol 2007;79(6):771–781PubMedCrossRefGoogle Scholar
  17. [17]
    Wężowska M, Giedrys-Kalemba S, Szymaniak L, Borowiec-Chłopek Ż, Konstanty-Kurkiewicz V, Menkiszak J. Risk factors for cervical cancer among young women. Central European Journal of Medicine. Central European Journal of Medicine 2012, DOI: 10.2478/s11536-012-0063-3Google Scholar
  18. [18]
    IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 90, Human Papillomaviruses, IARC Monographs 2007Google Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Zivile Gudleviciene
    • 1
  • Daiva Kanopiene
    • 1
  • Janina Didziapetriene
    • 1
  • Raisa Smolyakova
    • 2
  • Ekaterina Gutkovskaya
    • 2
  • Alexander Zhukovec
    • 2
  • Galina Kostevich
    • 2
  1. 1.Institute of OncologyVilnius UniversityVilniusLithuania
  2. 2.N.N. Alexandrov National Cancer Center, LesnojMinsk regionBelarus

Personalised recommendations